(Q83770417)

English

Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-l

scientific article published on 30 March 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460837%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460837%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

9

object named as

Jun Hyuk Hong

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460837%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

10

object named as

Choung-Soo Kim

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460837%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

11

object named as

Hanjong Ahn

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460837%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

8

object named as

Cheryn Song

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460837%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

Kwonoh Park

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460837%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Jae-Lyun Lee

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460837%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Inkeun Park

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460837%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Seongjoon Park

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460837%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Yongcheol Ahn

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460837%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Jin-Hee Ahn

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460837%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Shin Ahn

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460837%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

publication date

30 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460837%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Medical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460837%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

29

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460837%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460837%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

3291-3297

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460837%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

https://scigraph.springernature.com/pub.10.1007/s12032-012-0227-7

0 references

Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A quantitative analysis of kinase inhibitor selectivity

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential sorafenib and sunitinib for renal cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22460837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83770417&oldid=1890242400"